Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

Kuehne+Nagel supports Sanofi in multiple countries worldwide, including Hungary, the UK, and the UAE, by providing customised ...

An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction ...

Sanofi India's board has recommended a final dividend of ₹117 per equity share of ₹10 face value, subject to shareholder ...

Sanofi & Teva's IBD drug duvakitug shows promise in Phase 2b with €1B sales potential by 2032, faces competition from Roivant ...